Phil Bergman

Beantown Biotech is a Boston-based contract research organization (CRO) built for drug discovery, specializing in assay development and screening for target validation through lead optimization. As a boutique CRO, we partner closely with biopharma teams to provide flexible, expert-driven research support across every stage of discovery. Our approach is designed with your success at the forefront, by allowing clients to focus resources on achieving critical research milestones, while reducing operational overhead. We combine rigorous science with responsive, transparent collaboration, delivering high-quality, reproducible data on timelines that support confident decision-making. Whether project-based or fully supported through our Dedicated Discovery BTBT+ service plans, we scale quickly as your programs evolve, delivering the execution needed to move your research forward with confidence. We operate as a true extension of your team, as your “lab down the hall,” with direct access to experienced scientists and open lines of communication at every step. Capabilities include: • Biochemical and cell-based assays (AlphaLISA, HTRF, HiBiT, NanoBRET, CTG, CyQuant, ELISA, DiscoverX, luminescence, fluorescence) • MesoScale Discovery (MSD) assays • Flow cytometry • High-content imaging (In Cell 6500HS, Operetta) • Live-cell imaging (IncuCyte S3) • dPCR • qPCR • Jess Western • Biophysical characterization (MST – Monolith, Tycho NT6) Visit our website to request more information or a quote: www.beantownbiotech.com